SNGX - Soligenix, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.1000
+0.0600 (+5.77%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.0400
Open1.0500
Bid1.0100 x 1000
Ask1.1200 x 900
Day's Range1.0000 - 1.1000
52 Week Range0.6500 - 2.2000
Volume69,135
Avg. Volume151,290
Market Cap21.543M
Beta (3Y Monthly)1.60
PE Ratio (TTM)N/A
EPS (TTM)-0.5260
Earnings DateAug 19, 2019 - Aug 23, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.63
Trade prices are not sourced from all markets
  • Moleculin Completes Enrollment in Early-Stage Cancer Study
    Zacks

    Moleculin Completes Enrollment in Early-Stage Cancer Study

    Moleculin (MBRX) reaches enrollment target in a clinical study evaluating its p-STAT3 inhibitor, WP1220, as a treatment for cutaneous T-cell lymphoma, a form of skin cancer.

  • PR Newswire

    Soligenix Announces $150,000 NIH Small Business Innovation Research Award Supporting Evaluation of SGX942 in Pediatric Indications

    Exploring Dusquetide in Broader Populations PRINCETON, N.J. , Aug. 15, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ...

  • PR Newswire

    Soligenix Announces Recent Accomplishments And Second Quarter 2019 Financial Results

    PRINCETON, N.J., Aug. 13, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2019. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "It is an exciting time for Soligenix. We are now approaching data read-out in two Phase 3 clinical programs.

  • Zacks Small Cap Research

    SNGX: What to Expect from the Upcoming Interim Analysis of SGX942

    Soligenix, Inc. (SNGX) is a biopharmaceutical company currently conducting two pivotal Phase 3 clinical trials with its lead development compounds. • SGX301 is in a Phase 3 trial for the treatment of cutaneous T cell lymphoma (CTCL). • SGX942 is in a Phase 3 clinical trial for the treatment of oral mucositis in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • PR Newswire

    Soligenix Announces Conference Presentations Demonstrating Formulations of Single and Multivalent Ebola Subunit Vaccines

    PRINCETON, N.J. , July 31, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...

  • PR Newswire

    Soligenix Receives European Patents for Oral BDP in the Treatment of Acute Radiation Injury of the Gastrointestinal Tract

    SGX201 and OrbeShield® are proprietary oral formulations of BDP that function as mucosally delivered steroidal treatments for the GI tract while minimizing systemic steroid side effects, including risk of severe infection.  SGX201 utilizes an enteric coated tablet to deliver steroid to the distal GI tract, while OrbeShield® employs both immediate and delayed release, enteric-coated formulations to cover both the proximal and distal GI tract.  Due to the low systemic bioavailability of BDP, these formulations maximize anti-inflammatory steroid action at the site of injury, while minimizing common side effects of steroids, including immune suppression, enabling their use in expanded populations.

  • Zacks Small Cap Research

    SNGX: Multiple Important Catalysts on the Horizon…

    Soligenix, Inc. (SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and biodefense. In April 2019, Soligenix announced that the Phase 3 trial of SGX942 had reached the enrollment target to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC).

  • PR Newswire

    Soligenix Announces Appointment of Diane L. Parks to its Board of Directors

    Strengthens marketing and commercial expertise PRINCETON, N.J. , July 8, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ...

  • PR Newswire

    Soligenix to Present RiVax® Program at the 13ᵗʰ Annual CounterACT Network Research Symposium

    PRINCETON, N.J., June 13, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Dr. Oreola Donini, Chief Scientific Officer, will be presenting data from the ricin toxin vaccine (RiVax®) program describing development of the vaccine under the Food and Drug Administration (FDA) Animal Rule.  The presentation will be given at the upcoming 13th Annual CounterACT Network Research Symposium on June 18-20, 2019 to be held at the New York Academy of Sciences, NY.

  • PR Newswire

    Soligenix Announces $600,000 Subaward Supporting Evaluation of Innate Defense Regulator Platform Technology as a Medical Countermeasure for Bacterial Threat Agents

    PRINCETON, N.J., May 28, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Soligenix will be participating in a biodefense contract for the development of medical countermeasures against bacterial threat agents, with Soligenix awarded a subcontract of approximately $600,000 over 3 years. Innate Defense Regulators (IDRs) regulate the innate immune system to simultaneously reduce inflammation, eliminate infection and enhance tissue healing.  IDRs have no direct antibiotic activity but modulate host responses, increasing survival after infections with a broad range of bacterial Gram-negative and Gram-positive pathogens including both antibiotic sensitive and resistant strains, as well as accelerating resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- or radiation-therapy.

  • Zacks Small Cap Research

    SNGX: Interim Analysis for SGX942 Phase 3 Trial Expected in Sep. 2019…

    On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • PR Newswire

    Soligenix Announces Recent Accomplishments And First Quarter 2019 Financial Results

    PRINCETON, N.J., May 14, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2019. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We have completed the approximate 90 subject enrollment necessary to support the interim efficacy analysis of our pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy. This interim analysis, to be conducted by the independent Data Monitoring Committee (DMC) for the trial, is anticipated to occur in September 2019.

  • Zacks Small Cap Research

    SNGX: Enrollment Target Reached for Interim Analysis of SGX942 Phase 3 Trial…

    On April 18, 2019, Soligenix, Inc. (SNGX) announced that it has reached the enrollment target for the Phase 3 clinical trial of SGX942 (dusquetide) to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC). The Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial is evaluating SGX942 for the treatment of sever oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy.

  • PR Newswire

    Soligenix -- Advancing to Important Inflection Points With Two Pivotal Phase 3 Clinical Trials

    PRINCETON, N.J., April 23, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.  The content of this letter is provided below.

  • PR Newswire

    Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer

    PRINCETON, N.J., April 18, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has reached a significant milestone in the Phase 3 clinical study (the "DOM-INNATE" study) for SGX942 (dusquetide) in the treatment of oral mucositis in patients with head and neck cancer (HNC). Patient enrollment is sufficient to support the planned interim efficacy analysis by the independent Data Monitoring Committee (DMC).

  • PR Newswire

    Soligenix Receives $611,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program

    PRINCETON, N.J., April 15, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has received approximately $611,000, net of transaction costs, in non-dilutive financing via the state of New Jersey's Technology Business Tax Certificate Transfer Program. This competitive program enables approved technology and biotechnology businesses to sell their unused Net Operating Loss (NOL) Carryovers and unused Research and Development (R&D) Tax Credits to unaffiliated, profitable corporate taxpayers in the state of New Jersey.

  • PR Newswire

    Soligenix and the European Medicines Agency Pediatric Committee Reach Agreement on the Pediatric Investigation Plan for SGX942

    PRINCETON, N.J., April 9, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Pediatric Committee (PDCO) of the European Medicines Agency (EMA) agreed to the Company's Pediatric Investigation Plan (PIP) for SGX942 (dusquetide).  It was also agreed that the Company may defer conducting the PIP until successful completion of its ongoing pivotal Phase 3 clinical study evaluating SGX942 as a treatment for oral mucositis in patients with head and neck cancer (HNC). As part of the regulatory process for the registration of new medicines in Europe, pharmaceutical companies are required to provide a PIP outlining their strategy for investigation of the new medicinal product in the pediatric population.

  • PR Newswire

    Soligenix Receives US Patent for Dusquetide Related Analogs

    PRINCETON, N.J., April 4, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the US Patent Office will issue the patent titled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity" on April 9, 2019.  The new patent (#10,253,068) claims composition of matter for novel innate defense regulator (IDR) analogs, expanding patent protection to more diverse analog structures. Therapeutic use claims in oral mucositis, colitis, and infectious disease, both alone and in conjunction with antibiotics, will also issue.

  • Zacks Small Cap Research

    SNGX: Interim Analysis of SGX942 in Oral Mucositis in Third Quarter of 2019…

    Soligenix, Inc. (SNGX) is currently conducting the randomized, multinational, double blind, placebo controlled Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE immunity) clinical trial, which is evaluating SGX942 (dusquetide) for the treatment of severe oral mucositis (OM) in patients with squamous cell carcinoma of the oral cavity and oropharynx undergoing chemoradiation therapy. Important secondary endpoints that are being evaluated include tumor progression and overall survival at 12 months.

  • PR Newswire

    Soligenix Announces Recent Accomplishments and Year-End 2018 Financial Results

    PRINCETON, N.J., March 26, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the year ended December 31, 2018. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We are actively enrolling patients in our pivotal double-blind, placebo-controlled Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy.

  • PR Newswire

    Soligenix to Present at the Boston Oncology Investor Conference 2019

    PRINCETON, N.J., March 11, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation at the Boston Oncology Investor Conference 2019 on Thursday, March 14 at 5:35 PM ET. The event will take place at 28 State Street, Boston, MA.

  • Zacks Small Cap Research

    SNGX: Innate Defense Regulators Offer New Approach to Treating Infections

    Soligenix, Inc. (SNGX) recently published a review of the potential clinical applications for innate defense regulators (IDRs), including the company’s lead IDR asset SGX942. IDRs modulate the innate immune response, which is composed of both physical barriers (e.g., skin, mucosal surfaces, etc.) as well as specialized myeloid and lymphoid sensor and effector cells (Gasteiger et al., 2017). IDRs exert their effects through binding of p62 (sequestosome-1), which is involved in a number of different innate immune signaling networks (Yu et al., 2009).

  • PR Newswire

    Soligenix Receives US Patent Expanding Protection for its Ricin Toxin Vaccine, RiVax®

    PRINCETON, N.J., Feb. 11, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the allowance of a new United States (US) patent protecting its ricin toxin vaccine, RiVax®.  The patent, titled "Multivalent Stable Vaccine Composition and Methods of making same", supports combination vaccines protecting against ricin intoxication as well as other toxins, such as those associated with anthrax. RiVax® is the Company's vaccine candidate for the prevention of death following exposure to a lethal dose of ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin.  The RiVax® antigen has demonstrated safety in two Phase 1 clinical studies.

  • PR Newswire

    Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate

    PRINCETON, N.J., Feb. 7, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of a scientific article demonstrating the successful thermostabilization of an Ebola subunit vaccine candidate. The article titled, "Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide", is published in the European Journal of Pharmaceutics and Biopharmaceutics online and is available here. As previously announced, Soligenix has been collaborating with the University of Hawai'i at Mānoa (UH Mānoa) and Hawaii Biotechnology, Inc. (HBI) on the development of a multivalent subunit vaccine for Ebola and Marburg infections.

  • PR Newswire

    Soligenix Receives European Patent for Dusquetide and Related Innate Defense Regulator Analogs

    PRINCETON, N.J., Jan. 23, 2019 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted the patent entitled "Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity."  The newly issued patent claims composition of matter of innate defense regulator (IDR) analogs, expanding patent protection around the Company's lead IDR, dusquetide.  Similar claims have been previously allowed in the United States (US) and are being pursued in other worldwide jurisdictions.